Amlotte Ex Rel. Amlotte v. United States

292 F. Supp. 2d 922, 2003 U.S. Dist. LEXIS 24102, 2003 WL 22801163
District Court, E.D. Michigan·Decided November 17, 2003·No. 01-10235-BC·Published·Cited by 8 cases

Opinion

OPINION AND ORDER GRANTING PLAINTIFF’S MOTION IN LIMINE

LAWSON, District Judge.

The plaintiffs have filed a complaint alleging that the minor plaintiff, Chelsey Amlotte, suffered damages as a result of medical malpractice committed by doctors at the Alcona Health Center in Lincoln, Michigan. That facility is a federally supported medical clinic, and its covered physicians are deemed employees of the Public Health Service. See 42 U.S.C. § 233(g). The plaintiffs’ claim, therefore, has been filed under the Federal Tort Claims Act (FTCA), 28 U.S.C. § 2671 et seq., which is their exclusive remedy against the clinic and its employees. See 42 U.S.C. § 233(a). Under the FTCA, the United States is liable for tort claims “in the same manner and to the same extent as a private individual under like circumstances.” 28 U.S.C. § 2674. A dispute has arisen between the parties as to an element of damages for which the United States may be liable. Specifically, the parties disagree on whether damages for the cost of Chelsey Amlotte’s future medical care may be reduced by the amount that may be paid by the Medicare program now in place to cover ailments of the type suffered by the minor plaintiff. The plaintiffs seek a resolution of this question through their motion styled as a motion in limine, in which they ask the Court to prevent the United States from offering at trial any evidence of future Medicare payments that could be set off against damages for future medical expenses.

Based on the analysis set forth in detail below, the Court finds that Michigan has altered the traditional common-law rule that prohibited setting off against damage *924 awards payments from collateral sources, such as insurance. The Michigan legislation explicitly sets forth those elements of damages that are subject to reduction by payments derived from collateral sources; damages for future medical expenses is not among the listed elements of damages. The Michigan legislation, however, did not alter the common-law rule that a defendant may set off direct payments made by a defendant to an injured party. Payments coming from government programs can be characterized as gratuitous benefits — in which case they would fall into the “direct payment” category — or proceeds that are in the nature of insurance — which would thus be treated as coming from a “collateral source.” The Court finds that the benefits that would be available to Chelsey Amlotte under both Part A and Part B of Medicare should be characterized as insurance benefits, and thus treated as a collateral source. Since payments from a collateral source may not be set off against future medical expenses under Michigan law, evidence of such payments would be irrelevant. The Court, therefore, will grant the plaintiffs’ motion in limine.

I.

Chelsey Amlotte’s parents took her to the Alcona Health Center for treatment of her ulcerative colitis. Some time after September 1994, Chelsey was administered the drug Asacol, which can and apparently did cause severe kidney damage to Chelsey. As a result, Chelsey Amlotte developed chronic interstitial nephritis with end stage renal disease (ESRD). The plaintiffs attribute Chelsey’s ESRD to the negligence of the medical personnel at the Alcona Health Center due to their failure to properly administer Asacol and monitor their patient to detect and promptly treat the harmful side-effects of the drug. From February to October 2000, Chelsey underwent renal dialysis, and received a kidney transplant at the end of that course. The plaintiffs allege that the medical evidence will show that Chelsey likely will require at least one more transplant at an undetermined time in the future, preceded by episodes of renal failure that will require treatment by dialysis for certain periods throughout her life.

Initially, Chelsey’s medical expenses were covered by private insurance available through her parents’ employment. After a 30-month period during which the private coverage was coordinated with Medicare, which apparently ended as of August 2002, the Medicare Program became Chelsey Amlotte’s primary medical payor for treatment of her ESRD. At present, therefore, although the Medicare benefits paid on Chelsey’s behalf have been minimal, it is expected that Medicare will cover most of Chelsey’s future medical expenses, including the costs of future transplants, anti-rejection medications, and dialysis.

The dispute over whether these future Medicare benefits may be set off against the cost of future medical care arose during pretrial settlement negotiations, in which the Court did not participate. The parties seek a resolution of the issue to help guide future discussions and to prepare to meet the evidence at trial.

II.

Free access — add to your briefcase to read the full text and ask questions with AI

Amlotte Ex Rel. Amlotte v. United States, 292 F. Supp. 2d 922, 2003 U.S. Dist. LEXIS 24102, 2003 WL 22801163 (E.D. Mich. 2003).

292 F. Supp. 2d 922 (Amlotte Ex Rel. Amlotte v. United States) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Blakemore v. City of Alpena
E.D. Michigan, 2022
Rollinger v. FCA us LLC
E.D. Michigan, 2022
Redmond v. United States
194 F. Supp. 3d 606 (E.D. Michigan, 2016)
Washington v. United States
17 F. Supp. 3d 1154 (S.D. Alabama, 2014)
Lopez v. Safeway Stores, Inc.
129 P.3d 487 (Court of Appeals of Arizona, 2006)